ELYXYB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Elyxyb, and what generic alternatives are available?
Elyxyb is a drug marketed by Scilex Pharms and is included in one NDA. There are six patents protecting this drug.
This drug has twenty-five patent family members in twelve countries.
The generic ingredient in ELYXYB is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the celecoxib profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Elyxyb
A generic version of ELYXYB was approved as celecoxib by TEVA on May 30th, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ELYXYB?
- What are the global sales for ELYXYB?
- What is Average Wholesale Price for ELYXYB?
Summary for ELYXYB
| International Patents: | 25 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 175 |
| Patent Applications: | 4,546 |
| Drug Prices: | Drug price information for ELYXYB |
| What excipients (inactive ingredients) are in ELYXYB? | ELYXYB excipients list |
| DailyMed Link: | ELYXYB at DailyMed |
Pharmacology for ELYXYB
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for ELYXYB
ELYXYB is protected by six US patents.
Patents protecting ELYXYB
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Oral composition of celecoxib for treatment of pain
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Scilex Pharms | ELYXYB | celecoxib | SOLUTION;ORAL | 212157-001 | May 5, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ELYXYB
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer Limited | Onsenal | celecoxib | EMEA/H/C/000466 Onsenal is indicated for the reduction of the number of adenomatous intestinal polyps in familial adenomatous polyposis (FAP), as an adjunct to surgery and further endoscopic surveillance (see section 4.4).The effect of Onsenal-induced reduction of polyp burden on the risk of intestinal cancer has not been demonstrated (see sections 4.4 and 5.1) |
Withdrawn | no | no | no | 2003-10-17 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ELYXYB
See the table below for patents covering ELYXYB around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 101994129 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 2017208069 | ⤷ Sign Up | |
| Russian Federation | 2745196 | ПЕРОРАЛЬНАЯ КОМПОЗИЦИЯ ЦЕЛЕКОКСИБА ДЛЯ ЛЕЧЕНИЯ БОЛИ (ORAL CELECOXIB COMPOSITION FOR PAIN TREATMENT) | ⤷ Sign Up |
| Russian Federation | 2708254 | Пероральная композиция целекоксиба для лечения боли (ORAL CELECOXIB COMPOSITION FOR TREATING PAIN) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2016191744 | ⤷ Sign Up | |
| Canada | 2987272 | COMPOSITION ORALE DE CELECOXIB POUR LE TRAITEMENT DE LA DOULEUR (ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ELYXYB
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0731795 | 10075033 | Germany | ⤷ Sign Up | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
